Advanced in X-Linked Retinal Dysplasia

Haluk A. Topaloglu

Istanbul, TR 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in X-Linked Retinal Dysplasia
Istanbul, TR 
OverviewLocationsClinical Research

Overview

Haluk Topaloglu practices in Istanbul, Turkey. Topaloglu is rated as an Advanced expert by MediFind in the treatment of X-Linked Retinal Dysplasia. Their top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Progressive Myoclonic Epilepsy, Duchenne Muscular Dystrophy, and Gastrostomy.

Their clinical research consists of co-authoring 131 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of X-Linked Retinal Dysplasia.

Locations

Istanbul, Turkey
Other Locations
Ankara, Turkey
Altindag, Turkey
Dokuz Eylul, Turkey
Yildirim Beyazit, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), Type 2C (LGMD2C/R5), and Type 2A (LGMD2A/R1)
Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), Type 2C (LGMD2C/R5), and Type 2A (LGMD2A/R1)
Enrollment Status: Recruiting
Publish Date: October 18, 2024
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency Treated With the Combination of Pyrimidine Nucleos(t)Ides as Well as Untreated Subjects to Collect Vital Status Data and Supporting Information
A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency Treated With the Combination of Pyrimidine Nucleos(t)Ides as Well as Untreated Subjects to Collect Vital Status Data and Supporting Information
Enrollment Status: Completed
Publish Date: September 01, 2023
Intervention Type: Other
View 2 Less Clinical Trial

131 Total Publications

Biallelic variants in ARHGAP19 cause a progressive inherited motor-predominant neuropathy.
Biallelic variants in ARHGAP19 cause a progressive inherited motor-predominant neuropathy.
Journal: The Journal of clinical investigation
Published: October 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Topaloglu's expertise for a condition
ConditionClose
    View All 29 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile